KemPharm Announces Research Affirming Serdexmethylphenidate's Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
globenewswire.com
news
2022-06-01 00:00:00

Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm's prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION, Fla., June 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc.Â (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that a manuscript summarizing the results of three clinical studies involving serdexmethylphenidate (SDX), KemPharm's prodrug of dexmethylphenidate (d-MPH), was published in the peer-reviewed journal, Current Medical Research & Opinion.
